• FDA says nasal spray for social anxiety disorder lacks abuse potential

    7 days ago - By Healio

    The FDA announced that PH94B, VistaGen Therapeutics' intranasal drug to treat acute social anxiety in adults, lacks the potential for abuse.
    Per a release, the FDA stated that both nonclinical and clinical data from the PALISADE phase 3 program found that receptor binding data do not show that PH94B has affinity for abuse-related sites, such as dopamine, opiate, and no additional nonclinical studies are required to evaluate the drug's abuse potential.
    “There are more than 25 million people in the United States suffering from social anxiety disorder, and many of them do not
    Read more ...